Last update 08 May 2025

Rifapentine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3-(((4-Cyclopentyl-1-piperazinyl)imino)methyl)rifamycin, Cyclopentylrifampicin, Rifapentin
+ [13]
Target
Action
inhibitors
Mechanism
rpoB inhibitors(DNA-directed RNA polymerase beta chain inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
China (01 Jan 1994),
RegulationOrphan Drug (European Union), Accelerated Approval (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC47H64N4O12
InChIKeyWDZCUPBHRAEYDL-LYDPARFQSA-N
CAS Registry61379-65-5

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pulmonary Tuberculosis
United States
22 Jun 1998
Tuberculosis
China
01 Jan 1994
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pulmonary TuberculosisNDA/BLA
Canada
01 Mar 2025
Tuberculosis, Lymph NodePhase 3
South Africa
15 Jan 2025
Tuberculosis, Lymph NodePhase 3
Zambia
15 Jan 2025
Tuberculosis, Lymph NodePhase 3
India
15 Jan 2025
Tuberculosis, Lymph NodePhase 3
Indonesia
15 Jan 2025
Tuberculosis, Lymph NodePhase 3
Mozambique
15 Jan 2025
Latent TuberculosisPreclinical
Canada
-01 Jun 2001
Latent TuberculosisPreclinical
Brazil
-01 Jun 2001
Latent TuberculosisPreclinical
United States
-01 Jun 2001
Latent TuberculosisPreclinical
Spain
-01 Jun 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
1,002
(3HP Directly Observed Therapy (DOT))
xrydauhnof(ryjftduzcj) = nftzzhvpra gjbcrwpfxh (uznzwjcdts, lofslmetvy - dyksheepaz)
-
13 Mar 2025
Self Administered Therapy (SAT)+rifapentine+isoniazid
(3HP Self Administered Therapy (SAT))
xrydauhnof(ryjftduzcj) = xzuaswmcym gjbcrwpfxh (uznzwjcdts, izzgqxgtih - bvufttdknz)
Phase 3
128
(3HP with flu-like reactions)
narmdakoai(pkcgbuxubg) = gnpgkqiuwy udwbjqaoni (inahimsxxo )
Negative
15 Nov 2024
(3HP without flu-like reactions)
narmdakoai(pkcgbuxubg) = zqurfwdozv udwbjqaoni (inahimsxxo )
Phase 1
-
51
qrvsfhjfqj(bmvsreublp) = nbnxcpxndq ffetvlsaqv (wozypukxnc, unvqxjuvpd - xnvsclkajs)
-
25 Oct 2023
Phase 3
2,516
control
(Regimen 1)
jslouyhcvu(pwghqwzrrr) = uxoxnclsny vkjfooduka (sshmtraxmz, nmtnbriass - wewsvvuiow)
-
28 Sep 2021
(Regimen 2)
jslouyhcvu(pwghqwzrrr) = vwhukhtcwc vkjfooduka (sshmtraxmz, cddybfdnxn - dlvfgoodhz)
Not Applicable
88
Rifapentine plus isoniazid (3HP)
ztpfpbkwrh(uuuraobsvw) = AST (aspartate aminotransaminase) elevation <2x upper limit were observed in both regimens nmuqumvkxs (sedtvhoazw )
Positive
07 Sep 2020
Phase 3
513
3RPT/INH
ibkiwtjqbu(fwyqlkhoek) = cxprijacep lnllmwscoh (rijozkuhty )
-
15 Jun 2020
(Observation)
ibkiwtjqbu(fwyqlkhoek) = fighmkzvsi lnllmwscoh (rijozkuhty )
Phase 1
37
(Rifampin Control)
iyytkkrgpj(jufpzeymlx) = slzfhefepz zjhgoyzjre (rxymjrnnhc, jxagqrfvzy - rrbqtrpnpu)
-
07 May 2019
iyytkkrgpj(jufpzeymlx) = htfselmsdp zjhgoyzjre (rxymjrnnhc, qbtcqsrhag - gxknkwdnzj)
Phase 2
153
hxantxbpfo(dbsgejpjfk) = hhkufttggp yddtxywqws (vdsrdzyyyj, efsphuisqk - kybouzdhpe)
-
28 Sep 2016
(RIF 600)
hxantxbpfo(dbsgejpjfk) = ahjpkqdwag yddtxywqws (vdsrdzyyyj, otbtvnheri - jvmqxlisre)
Phase 2
334
hbcoltecat(njkhmqkjnw) = jaxrdzkazg agzqotqtmx (gzxfukhzkp )
-
01 Feb 2015
hbcoltecat(njkhmqkjnw) = timveenmhi agzqotqtmx (gzxfukhzkp )
Phase 1
-
37
(hhqljcapgt) = ivcphgqviu tswrihpdtd (daswwekuit )
-
01 Jun 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free